A Randomized Trial of Closed-Loop Control in Children with Type 1 Diabetes
| Autor: | Breton, Marc, Kanapka, Lauren, Beck, Roy, Ekhlaspour, Laya, Forlenza, Gregory, Cengiz, Eda, Schoelwer, Melissa, Ruedy, Katrina, Jost, Emily, Carria, Lori, Emory, Emma, Hsu, Liana, Oliveri, Mary, Kollman, Craig, Dokken, Betsy, Weinzimer, Stuart, DeBoer, Mark, Buckingham, Bruce, Cherñavvsky, Daniel, Wadwa, R. Paul, Research Group, iDCL Trial, Renard, Eric |
|---|---|
| Přispěvatelé: | University of Virginia [Charlottesville], Jaeb Center for Health Research, Stanford University, Barbara Davis Center for Childhood Diabetes (BDC), University of Colorado Anschutz [Aurora], Yale University School of Medicine, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
MESH: Hypoglycemia MEDLINE Insulin delivery MESH: Insulin 030204 cardiovascular system & hematology Artificial pancreas law.invention 03 medical and health sciences MESH: Insulin Infusion Systems MESH: Diabetic Ketoacidosis 0302 clinical medicine Randomized controlled trial law Internal medicine Diabetes mellitus MESH: Child MESH: Hypoglycemic Agents medicine 030212 general & internal medicine Glycemic MESH: Adolescent Type 1 diabetes MESH: Humans business.industry MESH: Injections Subcutaneous General Medicine medicine.disease MESH: Male 3. Good health MESH: Glycated Hemoglobin A medicine.anatomical_structure MESH: Infusion Pumps Implantable MESH: Blood Glucose Pancreas business MESH: Diabetes Mellitus Type 1 MESH: Female MESH: Pancreas Artificial [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | New England Journal of Medicine New England Journal of Medicine, Massachusetts Medical Society, 2020, 383 (9), pp.836-845. ⟨10.1056/NEJMoa2004736⟩ |
| ISSN: | 0028-4793 1533-4406 |
| DOI: | 10.1056/NEJMoa2004736⟩ |
| Popis: | International audience; Background: A closed-loop system of insulin delivery (also called an artificial pancreas) may improve glycemic outcomes in children with type 1 diabetes.Methods: In a 16-week, multicenter, randomized, open-label, parallel-group trial, we assigned, in a 3:1 ratio, children 6 to 13 years of age who had type 1 diabetes to receive treatment with the use of either a closed-loop system of insulin delivery (closed-loop group) or a sensor-augmented insulin pump (control group). The primary outcome was the percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter, as measured by continuous glucose monitoring.Results: A total of 101 children underwent randomization (78 to the closed-loop group and 23 to the control group); the glycated hemoglobin levels at baseline ranged from 5.7 to 10.1%. The mean (±SD) percentage of time that the glucose level was in the target range of 70 to 180 mg per deciliter increased from 53±17% at baseline to 67±10% (the mean over 16 weeks of treatment) in the closed-loop group and from 51±16% to 55±13% in the control group (mean adjusted difference, 11 percentage points [equivalent to 2.6 hours per day]; 95% confidence interval, 7 to 14; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|